Skip to content
Wenlo
Sign in
← Markets

Kodiak Sciences Inc.

BAKER BROS. ADVISORS LP (Director) buys KOD shares

4KODFiled Sep 30, 2026, 12:31 PM ET· Period Sep 28, 2026

About this filing

Kodiak Sciences Inc. (KOD) filed Form 4 (insider transaction) with the SEC on Sep 30, 2026. Form 4 reports a company insider’s trades in the company’s shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider 1
BAKER BROS. ADVISORS LP · Director
Insider 2
667, L.P. · Director
Insider 3
Baker Bros. Advisors (GP) LLC · Director
Insider 4
Baker Brothers Life Sciences LP · Director
Insider 5
Felix Baker · Director
Insider 6
Julian Baker · Director
DateTransactionSharesPriceValueHeld afterOwnership
Sep 28, 2026P · purchaseFootnotes F1, F2, F3, F4+186$86.72$16,130.241,629,628Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F1, F3, F4, F5+3,114$86.72$270,051.3719,519,021Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F6, F2, F3, F4+957$86.81$83,081.191,630,585Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F6, F3, F4, F5+16,036$86.81$1,392,152.5119,535,057Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F7, F2, F3, F4+3,790$86.94$329,510.561,634,375Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F7, F3, F4, F5+63,539$86.94$5,524,214.0919,598,596Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F8, F2, F3, F4+4,485$87.51$392,466.651,638,860Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F8, F3, F4, F5+75,176$87.51$6,578,388.6419,673,772Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F9, F2, F3, F4+5,880$88.57$520,774.551,644,740Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F9, F3, F4, F5+98,561$88.57$8,729,261.9419,772,333Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F10, F2, F3, F4+6,428$88.65$569,816.491,651,168Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F10, F3, F4, F5+107,772$88.65$9,553,556.7119,880,105Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F11, F2, F3, F4+4,932$89.60$441,924.961,656,100Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F11, F3, F4, F5+82,673$89.60$7,407,798.4219,962,778Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F12, F2, F3, F4+11,729$89.86$1,053,915.161,667,829Indirect (See Footnotes)
Sep 28, 2026P · purchaseFootnotes F12, F3, F4, F5+196,608$89.86$17,666,310.1420,159,386Indirect (See Footnotes)
Sep 29, 2026P · purchaseFootnotes F13, F2, F3, F4+619$84.24$52,145.861,668,448Indirect (See Footnotes)
Sep 29, 2026P · purchaseFootnotes F13, F3, F4, F5+10,381$84.24$874,517.2420,169,767Indirect (See Footnotes)
Sep 29, 2026P · purchaseFootnotes F14, F2, F3, F4+1,195$85.40$102,056.591,669,643Indirect (See Footnotes)
Sep 29, 2026P · purchaseFootnotes F14, F3, F4, F5+20,031$85.40$1,710,707.4920,189,798Indirect (See Footnotes)
Sep 29, 2026P · purchaseFootnotes F15, F2, F3, F4+84$85.89$7,214.381,669,727Indirect (See Footnotes)
Sep 29, 2026P · purchaseFootnotes F15, F3, F4, F5+1,416$85.89$121,613.8720,191,214Indirect (See Footnotes)
Footnotes
  1. F1 The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $86.70 to $86.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  2. F2 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  3. F3 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  4. F4 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  5. F5 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
  6. F6 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  7. F7 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.465, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  8. F8 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $87.03 to $88.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  9. F9 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.25 to $88.97, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  10. F10 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.01 to $89.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  11. F11 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.32 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  12. F12 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.11 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  13. F13 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.81 to $84.65, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  14. F14 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.16 to $85.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  15. F15 The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.82 to $85.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Remarks: Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Kodiak Sciences Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer. This is the third of three Forms 4 reporting changes in beneficial ownership. Due to space limitations in Form 4 we are thus filing these three Forms 4.

More KOD filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.